Pramipexole: A dopamine D3-preferring compound that lacks interactions with sigma binding sites

David Wallace, R. M. Booze

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Compounds which were previously thought to be D2- or D3-selective have recently been demonstrated to interact with sigma binding sites. The present studies examined: 1) displacement of [3H]pramipexole binding to transfected cells and striatum or nucleus accumbens homogenates by haloperidol and 1,3-di(2-toyl)guanidine (DTG) and 2) pramipexole, a D3 receptor agonist, displacement of [3H]1,3-di(2-toyl)guanidine ([3H]DTG) from dopamine-insensitive sigma binding sites in striatum and nucleus accumbens homogenates. [3H]Pramipexole (2 nM) labeled 20.7 ± 3.1 fmol/mg protein in cell membranes which was displaced 91.4% by 1 μM haloperidol and 36.8% by 1 μM DTG suggesting selectivity for D3 receptors versus sigma receptors. Unlabeled DTG displaced [3H]pramipexole binding to cell membranes with low affinity (7.4 ± 0.5 μM). In both striatum and nucleus accumbens, [3H]DTG identified dopamine-insensitive sites with moderate affinity (297 ± 15.8 fmol/mg; 29.0 ± 5.5 nM and 255 ± 5.8 fmol/mg; 26.3 ± 4.2 nM, respectively) which was displaced by pramipexole with low affinity (IC50 > 1 μM). These data suggest that pramipexole, a D3-preferring agonist without interactions at sigma receptors as an agonist, might be efficacious in the treatment of neuropsychiatric disorders.

Original languageEnglish
Pages (from-to)177-183
Number of pages7
JournalNeuroscience Research Communications
Volume17
Issue number3
StatePublished - 1 Jan 1995

Fingerprint

Dopamine
Binding Sites
Nucleus Accumbens
sigma Receptors
Guanidine
Haloperidol
Inhibitory Concentration 50
pramipexole
D3 compound
Membrane Proteins
Cell Membrane

Keywords

  • Antipsychotic
  • D3 receptor
  • Pramipexole
  • Schizophrenia
  • Sigma receptor

Cite this

@article{d0430d7db36249369a292886b8102ea6,
title = "Pramipexole: A dopamine D3-preferring compound that lacks interactions with sigma binding sites",
abstract = "Compounds which were previously thought to be D2- or D3-selective have recently been demonstrated to interact with sigma binding sites. The present studies examined: 1) displacement of [3H]pramipexole binding to transfected cells and striatum or nucleus accumbens homogenates by haloperidol and 1,3-di(2-toyl)guanidine (DTG) and 2) pramipexole, a D3 receptor agonist, displacement of [3H]1,3-di(2-toyl)guanidine ([3H]DTG) from dopamine-insensitive sigma binding sites in striatum and nucleus accumbens homogenates. [3H]Pramipexole (2 nM) labeled 20.7 ± 3.1 fmol/mg protein in cell membranes which was displaced 91.4{\%} by 1 μM haloperidol and 36.8{\%} by 1 μM DTG suggesting selectivity for D3 receptors versus sigma receptors. Unlabeled DTG displaced [3H]pramipexole binding to cell membranes with low affinity (7.4 ± 0.5 μM). In both striatum and nucleus accumbens, [3H]DTG identified dopamine-insensitive sites with moderate affinity (297 ± 15.8 fmol/mg; 29.0 ± 5.5 nM and 255 ± 5.8 fmol/mg; 26.3 ± 4.2 nM, respectively) which was displaced by pramipexole with low affinity (IC50 > 1 μM). These data suggest that pramipexole, a D3-preferring agonist without interactions at sigma receptors as an agonist, might be efficacious in the treatment of neuropsychiatric disorders.",
keywords = "Antipsychotic, D3 receptor, Pramipexole, Schizophrenia, Sigma receptor",
author = "David Wallace and Booze, {R. M.}",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "17",
pages = "177--183",
journal = "Neuroscience Research Communications",
issn = "0893-6609",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

Pramipexole : A dopamine D3-preferring compound that lacks interactions with sigma binding sites. / Wallace, David; Booze, R. M.

In: Neuroscience Research Communications, Vol. 17, No. 3, 01.01.1995, p. 177-183.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pramipexole

T2 - A dopamine D3-preferring compound that lacks interactions with sigma binding sites

AU - Wallace, David

AU - Booze, R. M.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Compounds which were previously thought to be D2- or D3-selective have recently been demonstrated to interact with sigma binding sites. The present studies examined: 1) displacement of [3H]pramipexole binding to transfected cells and striatum or nucleus accumbens homogenates by haloperidol and 1,3-di(2-toyl)guanidine (DTG) and 2) pramipexole, a D3 receptor agonist, displacement of [3H]1,3-di(2-toyl)guanidine ([3H]DTG) from dopamine-insensitive sigma binding sites in striatum and nucleus accumbens homogenates. [3H]Pramipexole (2 nM) labeled 20.7 ± 3.1 fmol/mg protein in cell membranes which was displaced 91.4% by 1 μM haloperidol and 36.8% by 1 μM DTG suggesting selectivity for D3 receptors versus sigma receptors. Unlabeled DTG displaced [3H]pramipexole binding to cell membranes with low affinity (7.4 ± 0.5 μM). In both striatum and nucleus accumbens, [3H]DTG identified dopamine-insensitive sites with moderate affinity (297 ± 15.8 fmol/mg; 29.0 ± 5.5 nM and 255 ± 5.8 fmol/mg; 26.3 ± 4.2 nM, respectively) which was displaced by pramipexole with low affinity (IC50 > 1 μM). These data suggest that pramipexole, a D3-preferring agonist without interactions at sigma receptors as an agonist, might be efficacious in the treatment of neuropsychiatric disorders.

AB - Compounds which were previously thought to be D2- or D3-selective have recently been demonstrated to interact with sigma binding sites. The present studies examined: 1) displacement of [3H]pramipexole binding to transfected cells and striatum or nucleus accumbens homogenates by haloperidol and 1,3-di(2-toyl)guanidine (DTG) and 2) pramipexole, a D3 receptor agonist, displacement of [3H]1,3-di(2-toyl)guanidine ([3H]DTG) from dopamine-insensitive sigma binding sites in striatum and nucleus accumbens homogenates. [3H]Pramipexole (2 nM) labeled 20.7 ± 3.1 fmol/mg protein in cell membranes which was displaced 91.4% by 1 μM haloperidol and 36.8% by 1 μM DTG suggesting selectivity for D3 receptors versus sigma receptors. Unlabeled DTG displaced [3H]pramipexole binding to cell membranes with low affinity (7.4 ± 0.5 μM). In both striatum and nucleus accumbens, [3H]DTG identified dopamine-insensitive sites with moderate affinity (297 ± 15.8 fmol/mg; 29.0 ± 5.5 nM and 255 ± 5.8 fmol/mg; 26.3 ± 4.2 nM, respectively) which was displaced by pramipexole with low affinity (IC50 > 1 μM). These data suggest that pramipexole, a D3-preferring agonist without interactions at sigma receptors as an agonist, might be efficacious in the treatment of neuropsychiatric disorders.

KW - Antipsychotic

KW - D3 receptor

KW - Pramipexole

KW - Schizophrenia

KW - Sigma receptor

UR - http://www.scopus.com/inward/record.url?scp=0028971625&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028971625

VL - 17

SP - 177

EP - 183

JO - Neuroscience Research Communications

JF - Neuroscience Research Communications

SN - 0893-6609

IS - 3

ER -